Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2
- PMID: 35618703
- PMCID: PMC9135681
- DOI: 10.1038/s41467-022-30580-5
Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2
Abstract
The Omicron SARS-CoV-2 has several distinct sublineages, among which sublineage BA.1 is responsible for the initial Omicron surge and is now being replaced by BA.2 worldwide, whereas BA.3 is currently at a low frequency. The ongoing BA.1-to-BA.2 replacement underscores the importance to understand the cross-neutralization among the three Omicron sublineages. Here we test the neutralization of BA.1-infected human sera against BA.2, BA.3, and USA/WA1-2020 (a strain isolated in late January 2020). The BA.1-infected sera neutralize BA.1, BA.2, BA.3, and USA/WA1-2020 SARS-CoV-2s with geometric mean titers (GMTs) of 445, 107, 102, and 16, respectively. Thus, the neutralizing GMTs against heterologous BA.2, BA.3, and USA/WA1-2020 are 4.2-, 4.4-, and 28.4-fold lower than the GMT against homologous BA.1, respectively. These findings have implications in COVID-19 vaccine strategy.
© 2022. The Author(s).
Conflict of interest statement
X.X. and P.-Y.S. have filed a patent on the reverse genetic system. J.Z., C.K., X.X., and P.-Y.S. received compensation from Pfizer for COVID-19 vaccine development. Other authors declare no competing interests.
Figures

Similar articles
-
Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages.Emerg Microbes Infect. 2023 Dec;12(1):e2161422. doi: 10.1080/22221751.2022.2161422. Emerg Microbes Infect. 2023. PMID: 36594261 Free PMC article.
-
Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine.Nat Commun. 2022 Jun 23;13(1):3602. doi: 10.1038/s41467-022-30681-1. Nat Commun. 2022. PMID: 35739094 Free PMC article.
-
Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection.Emerg Microbes Infect. 2022 Dec;11(1):1828-1832. doi: 10.1080/22221751.2022.2099305. Emerg Microbes Infect. 2022. PMID: 35792746 Free PMC article. Clinical Trial.
-
Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of the original mRNA vaccine.Cell Rep. 2022 Nov 29;41(9):111729. doi: 10.1016/j.celrep.2022.111729. Epub 2022 Nov 10. Cell Rep. 2022. PMID: 36402138 Free PMC article.
-
SARS-CoV-2 evolution in the Omicron era.Nat Microbiol. 2023 Nov;8(11):1952-1959. doi: 10.1038/s41564-023-01504-w. Epub 2023 Oct 16. Nat Microbiol. 2023. PMID: 37845314 Review.
Cited by
-
SARS-CoV-2 Evolution: Implications for Diagnosis, Treatment, Vaccine Effectiveness and Development.Vaccines (Basel). 2024 Dec 28;13(1):17. doi: 10.3390/vaccines13010017. Vaccines (Basel). 2024. PMID: 39852796 Free PMC article. Review.
-
The Increased Amyloidogenicity of Spike RBD and pH-Dependent Binding to ACE2 May Contribute to the Transmissibility and Pathogenic Properties of SARS-CoV-2 Omicron as Suggested by In Silico Study.Int J Mol Sci. 2022 Nov 4;23(21):13502. doi: 10.3390/ijms232113502. Int J Mol Sci. 2022. PMID: 36362302 Free PMC article.
-
Global Expansion of SARS-CoV-2 Variants of Concern: Dispersal Patterns and Influence of Air Travel.medRxiv [Preprint]. 2022 Nov 27:2022.11.22.22282629. doi: 10.1101/2022.11.22.22282629. medRxiv. 2022. Update in: Cell. 2023 Jul 20;186(15):3277-3290.e16. doi: 10.1016/j.cell.2023.06.001. PMID: 36451885 Free PMC article. Updated. Preprint.
-
Short-Read and Long-Read Whole Genome Sequencing for SARS-CoV-2 Variants Identification.Viruses. 2025 Apr 18;17(4):584. doi: 10.3390/v17040584. Viruses. 2025. PMID: 40285027 Free PMC article.
-
Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages.Emerg Microbes Infect. 2023 Dec;12(1):e2161422. doi: 10.1080/22221751.2022.2161422. Emerg Microbes Infect. 2023. PMID: 36594261 Free PMC article.
References
-
- Lyngse FP, et al. Transmission of SARS-CoV-2 omicron VOC subvariants BA.1 and BA.2: evidence from danish households. BioRxiv. 2022 doi: 10.1101/2022.01.28.22270044. - DOI
-
- Kurhade, C. et al. Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine. BioRxivhttps://biorxiv.org/cgi/content/short/2022.2003.2024.485633v485631 (2022).
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous